TuHURA Biosciences Stock
TuHURA Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- James A. Bianco
- Employees
- 22
- Market cap
- $112 M
- IPO
- 22/02/2013
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments.…
TuHURA Biosciences stock: price history
1D
-3.8%
1W
-10.2%
1M
-13.3%
6M
-39.7%
YTD
+132.6%
1Y
-26.7%
2Y
-82.2%
5Y
-95.9%
10Y
-99.9%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~11% weaker price swings than usual
Ask the agents about TuHURA Biosciences
Analyst assessment of TuHURA Biosciences
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 18/08/2026
TuHURA Biosciences stock metrics
P/E
-3.26
P/B
6.09
EV/EBITDA
-3.79
RETURN ON EQUITY
-49.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
62.3%
FLOAT SHARES
39,701,045
AVG. DAILY VOLUME (30D)
214,905
Insider transactions (SEC)
Bianco James A.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about TuHURA Biosciences stock
What does TuHURA Biosciences do?
TuHURA Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James A. Bianco, the company employs around 22 people.
The IPO was on 22/02/2013; the stock trades on NASDAQ under the ticker HURA.
What do analysts say about TuHURA Biosciences stock?
3 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
This is an external assessment, not a statement by Market Jury.
When does TuHURA Biosciences report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does TuHURA Biosciences pay a dividend?
No, TuHURA Biosciences currently does not pay a dividend.
Which stocks are comparable to TuHURA Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get TuHURA Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess TuHURA Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.